iodine I 131 monoclonal antibody 3F8

Iodine I 131 monoclonal antibody 3F8 is a radiopharmaceutical consisting of the murine IgG3 monoclonal antibody 3F8 labeled with the radioisotope Iodine-131. It specifically targets the disialoganglioside GD2, an antigen that is highly expressed on the surface of neuroblastoma cells and other tumors derived from the neuroectoderm, such as melanoma and certain brain cancers. Developed primarily by Memorial Sloan Kettering Cancer Center, this agent is used in radioimmunotherapy (RIT) to deliver localized radiation directly to tumor cells. The Iodine-131 isotope emits beta particles that induce DNA damage and cell death in target tissues, while its gamma emission allows for nuclear imaging and dosimetry. It has been investigated both intravenously for systemic disease and intrathecally/intraventricularly for the treatment of leptomeningeal metastases and central nervous system tumors to bypass the blood-brain barrier.

Other names

Iodine-131 labeled anti-GD2 monoclonal antibody 3F8Iodine131 labeled anti-GD2 monoclonal antibody 3F8Iodine 131 labeled anti-GD2 monoclonal antibody 3F8I-131 anti-GD2 3F8I131 anti-GD2 3F8I 131 anti-GD2 3F8Radiolabeled 3F8Radiolabeled3F8Radiolabeled-3F8Murine monoclonal antibody 3F8, I-131 labeled